Sanofi
lunsekimig
respiratory diseases
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for lunsekimig in respiratory diseases are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“encouraging phase 2 data for lunsekimig in respiratory diseases”